Corey Davis
Stock Analyst at HC Wainwright & Co.
(3.00)
# 1,506
Out of 5,111 analysts
17
Total ratings
75%
Success rate
25.83%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Corey Davis
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| NKTR Nektar Therapeutics | Reiterates: Neutral | $480 → $390 | $54.70 | +612.98% | 5 | May 12, 2020 | |
| SCYX SCYNEXIS | Assumes: Buy | $50 | $0.65 | +7,641.14% | 3 | May 7, 2018 | |
| VTVT vTv Therapeutics | Downgrades: Neutral | $560 → $40 | $34.37 | +16.38% | 2 | Apr 10, 2018 | |
| LPCN Lipocine | Initiates: Buy | $170 | $3.17 | +5,262.78% | 1 | Mar 29, 2018 | |
| VNDA Vanda Pharmaceuticals | Initiates: Buy | $20 | $6.23 | +221.03% | 2 | Jan 19, 2018 | |
| PCRX Pacira BioSciences | Initiates: Buy | $50 | $26.29 | +90.19% | 3 | Jan 19, 2018 | |
| JAZZ Jazz Pharmaceuticals | Initiates: Neutral | $144 | $167.50 | -14.03% | 1 | Aug 25, 2017 |
Nektar Therapeutics
May 12, 2020
Reiterates: Neutral
Price Target: $480 → $390
Current: $54.70
Upside: +612.98%
SCYNEXIS
May 7, 2018
Assumes: Buy
Price Target: $50
Current: $0.65
Upside: +7,641.14%
vTv Therapeutics
Apr 10, 2018
Downgrades: Neutral
Price Target: $560 → $40
Current: $34.37
Upside: +16.38%
Lipocine
Mar 29, 2018
Initiates: Buy
Price Target: $170
Current: $3.17
Upside: +5,262.78%
Vanda Pharmaceuticals
Jan 19, 2018
Initiates: Buy
Price Target: $20
Current: $6.23
Upside: +221.03%
Pacira BioSciences
Jan 19, 2018
Initiates: Buy
Price Target: $50
Current: $26.29
Upside: +90.19%
Jazz Pharmaceuticals
Aug 25, 2017
Initiates: Neutral
Price Target: $144
Current: $167.50
Upside: -14.03%